no Phase II or III trials published Most common AOD-9604 side effect / Injection-site reaction (redness, swelling) Most common reported MOTS-c side effect / Transient flushing and mild GI discomfort (anecdotal, not trial-confirmed) Growth hormone axis impact / AOD-9604 does not activate the GH receptor
NAD+, on the other hand, is a critical coenzyme involved in DNA repair, energy production, and cellular health
Insurance eligibility depends on your background, insurer, scope of practice, prescriber arrangements where relevant and any hands-on training requirements
Case reports describe telogen effluvium after B12 injections, resolving post-discontinuation
Ipamorelin acetate was placed on the FDA's Category 2 bulk substances list in 2023, then removed from Category 2 in September 2024 after the nominator withdrew the nomination, leaving its compounding status pending Pharmacy Compounding Advisory Committee review